Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis.

Journal: Hepatology communications
Published Date: Aug 16, 2017

Abstract

In contrast to patients with viral hepatitis, patients with nonalcoholic fatty liver disease (NAFLD) can progress to hepatocellular carcinoma during the initial stages of liver fibrosis. Development and implementation of noninvasive methods for diagnosis and progression prediction are important for effective NAFLD surveillance. Mac-2 binding protein (Mac-2bp) is a useful nonalcoholic steatohepatitis (NASH) diagnosis biomarker and a powerful prediction biomarker for NAFLD fibrosis stage. agglutinin (WFA)-positive Mac-2bp (WFA-M2BP) is a novel serum fibrosis biomarker for chronic hepatitis C that has clinical validity. Mac-2bp and WFA-M2BP are also clinical NAFLD biomarker candidates. We examined the efficacy of Mac-2bp and WFA-M2BP for NAFLD assessment using patients with biopsy-proven NAFLD (n = 510; NAFLD cohort) and subjects who received a health check-up (n = 2,122; check-up cohort). In the NAFLD cohort, we set the fibrosis predicting cutoff values as 1.80 (F1), 2.21 (F2), and 2.24 μg/mL (F3). In the subjects with fatty liver from the check-up cohort (n = 1,291), the serum Mac-2bp levels were >1.80 μg/mL in 38.6% of the subjects (n = 498), and >2.24 μg/mL in 24.6% of the subjects (n = 318). The NAFLD cohort results indicated that Mac-2bp and WFA-M2BP were equally useful for NASH diagnosis. During the early stages of fibrosis (F1, F2), the increase in Mac-2bp was statistically significant but WFA-M2BP did not increase. Logistic regression analysis revealed that Mac-2bp was an independent determinant for the prediction of advanced fibrosis stage (≥F2), even when adjusted for WFA-M2BP. Immunohistochemical staining of Mac-2bp revealed that hepatocytes strongly expressed Mac-2bp in patients with NAFLD. : Our results indicated that hepatocyte-derived Mac-2bp would be a useful single biomarker for NASH diagnosis and fibrosis stage prediction in patients with NAFLD. ( 2017;1:780-791).

Authors

  • Yoshihiro Kamada
    Departments of Molecular Biochemistry and Clinical Investigation Osaka University, Graduate School of Medicine Osaka Japan.
  • Masafumi Ono
    Division of Gastroenterology and HepatologyDepartment of Internal MedicineTokyo Women's Medical University Medical Center EastTokyoJapan.
  • Hideyuki Hyogo
    Department of GastroenterologyJA Hiroshima General HospitalHiroshimaJapan.
  • Hideki Fujii
    Department of HepatologyGraduate School of MedicineOsaka City UniversityOsakaJapan.
  • Yoshio Sumida
    Division of Hepatology and PancreatologyDepartment of Internal MedicineAichi Medical UniversityAichiJapan.
  • Makoto Yamada
    aMs New Otani Clinic Osaka Japan.
  • Kojiroh Mori
    Center for Digestive and Liver Diseases Nara City Hospital Nara Japan.
  • Saiyu Tanaka
    Center for Digestive and Liver DiseasesNara City HospitalNaraJapan.
  • Tomohiro Maekawa
    Departments of Molecular Biochemistry and Clinical Investigation Osaka University, Graduate School of Medicine Osaka Japan.
  • Yusuke Ebisutani
    Departments of Molecular Biochemistry and Clinical Investigation Osaka University, Graduate School of Medicine Osaka Japan.
  • Akiko Yamamoto
    Departments of Molecular Biochemistry and Clinical Investigation Osaka University, Graduate School of Medicine Osaka Japan.
  • Shinji Takamatsu
    Departments of Molecular Biochemistry and Clinical Investigation Osaka University, Graduate School of Medicine Osaka Japan.
  • Masashi Yoneda
    Division of Hepatology and PancreatologyDepartment of Internal MedicineAichi Medical UniversityAichiJapan.
  • Norifumi Kawada
    Department of Hepatology Osaka City University Graduate School of Medicine Osaka Japan.
  • Kazuaki Chayama
    Department of Gastroenterology and MetabolismApplied Life SciencesInstitute of Biomedical & Health SciencesHiroshima UniversityHiroshimaJapan.
  • Toshiji Saibara
    Department of Gastroenterology and Hepatology Kochi Medical School Kochi Japan.
  • Tetsuo Takehara
    Department of Gastroenterology and Hepatology Osaka University, Graduate School of Medicine Osaka Japan.
  • Eiji Miyoshi
    Departments of Molecular Biochemistry and Clinical Investigation Osaka University, Graduate School of Medicine Osaka Japan.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals